🔗 Share this article

As the US proceeds with sweeping adjustments to its immunization schedules, a particular individual appears in a surprising turn: Høeg, a Danish American physician and epidemiologist who first made her name by expressing skepticism about coronavirus shots throughout the pandemic and has focused upon potential fatalities following Covid immunization in her recent time at the US Food and Drug Administration (FDA).

Proposed Shifts to Childhood Vaccine Schedule

Agency leaders planned to reveal radical revisions to the childhood vaccine schedule in December, bringing the US with Denmark’s immunization schedule, according to reports – a substantial departure that would put the US at odds with a large portion of the international standard with no evidence for benefit. This reveal has been pushed back until the next year.

Instead of the director of the vaccine center, Høeg is scheduled to address the audience at the gathering. She was recently named acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to head the center this calendar year.

A New Direction at the Agency

This interim role might represent a closer partnership between the pharmaceutical and biologics divisions as Høeg and Dr. Prasad consolidate power at the regulatory agency – and it points to a increased emphasis upon rolling back long-standing vaccines at the FDA.

Høeg has repeatedly called for discontinuing some childhood immunization guidelines in the US to become more similar to the Danish model, a nation with comprehensive healthcare and a population about the size of the state of Wisconsin.

To date public appearances, she has persisted in emphasizing on vaccines – usually the purview of Dr. Prasad, director of the FDA’s CBER – as opposed to drug regulation.

Questions Over Qualifications

The appointee has no apparent background in pharmaceutical research, approval processes or management, which has been customary for former directors of the CBER. She has served at the FDA as a top consultant to the commissioner and CBER since March.

“She doesn’t seem to have the necessary background” for leading the drug-regulation department, said a neurologist and psychiatrist. “She’s never run a clinical trial. She lacks experience in managing a large organization. She is not an expert in pharmaceutical oversight.”

Previous commissioners of CBER would “understand laws and regulations and the science of drug development”, said Dr. Janet Woodcock. “Objectively, she has not acquired the kind of background that previous people who ran the center have had.”

The drug center has an vast workload at the FDA, Woodcock pointed out.

“The public just focuses on the novel medication approvals, but the off-patent medication office approves thousands of generic drugs. There’s a biologic copycat branch, over-the-counter program and more, and every single one must be supervised,” Woodcock explained. “The thing you overlook, that’s the thing that I always told people is going to cause problems.”

There is also, a major leadership aspect to the job, which supervises more than 5,000 employees. “It’s a massive administrative position, if you perform it correctly,” she concluded.

Agency Reaction and Contentious Initiatives

In response to inquiries about Dr. Høeg's fitness for the role and whether this selection indicates more teamwork among agency officials on immunizations, a press secretary said that the “inquiries are based on flawed assumptions”.

“Her resume is consistent with the responsibilities of her role,” the representative said, pointing to the time Høeg spent guiding the agency head on “drug safety and approval science, including computational safety modeling and immunization monitoring”.

As the temporary head, Dr. Høeg assumes responsibility for the agency head's new fast-track approval initiative, a controversial rapid therapy clearance system that allegedly concerned her preceding directors. “By what process are these medications being selected for this expedited pathway? Who is making the decisions?” Howard questioned. “There’s a lot of confidentiality happening at the agency right now.”

In general, he said, “the FDA looks to be trending towards less stringent oversight of all drugs, aside from immunizations.”

Documented Past Work on Vaccines

With vaccines, Høeg has a more established, if problematic, history, some experts have noted. She published a analysis using non-validated crowd-sourced reports to estimate the incidence of heart inflammation following COVID-19 vaccination. She counseled the Florida top health official Dr. Joseph Ladapo, who was said to have changed statistics to indicate COVID-19 vaccines are pose a greater threat than they are.

Among her “policy goals” for the current administration encompassed changing guidelines for new vaccines and halting “unnecessary” immunizations, she stated after the election on a online show. At the FDA, Høeg has allegedly suggested excluding teenage boys from obtaining Covid vaccinations.

“She is an all-around ideologue who commences with her conclusions and tailors the evidence to fit the evidence in a extremely disingenuous, untruthful manner,” Howard argued.

Consolidating Power and a “Revenge Tour”

Dr. Høeg joined fellow skeptics, {like|